Anal Cancer Clinical Trial
— HYPHYCAOfficial title:
Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Verified date | January 2019 |
Source | Centre Francois Baclesse |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Questionnaire to be completed by patients coming for PET to identify the predictive factors of physiological hypermetabolism of the anal canal
Status | Completed |
Enrollment | 644 |
Est. completion date | November 15, 2018 |
Est. primary completion date | November 15, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient 18 years old - Patient referred for 18F-FDG PET Exclusion Criteria: - History of surgery or anal and / or perineal and / or pelvic radiotherapy, whatever the indication - Patient deprived of liberty, under tutorship or curatorship - Any associated socio-educational, medical or psychological condition that could compromise the patient's ability to participate in the study (eg illiteracy, mental retardation, etc.) - Pregnant woman (classic contraindication of a PET scan) - Opposition of the patient to participate in the study |
Country | Name | City | State |
---|---|---|---|
France | Centre François Baclesse | Caen | |
France | CHU | Caen |
Lead Sponsor | Collaborator |
---|---|
Centre Francois Baclesse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of predictive factors for physiological hypermetabolism of the anal canal in 18F-FDG PET / CT | Confrontation in participants of hypermetabolism of the anal canal in PET with: number of stool/day and consistency of stool, medical history (by Answers to the specific questionnaire designed for the study) |
Only at the day of inclusion, during an appointment for a TEP exam | |
Primary | PET analysis of hypermetabolism of the anal canal | Visual analysis of hypermetabolism of the anal canal on a 3-point scale: 0: no hypermetabolism moderate hypermetabolism intense hypermetabolism |
Only at the day of inclusion, during an appointment for a TEP exam | |
Primary | CT scan with measurement | measurement of the largest rectal diameter in mm. | Only at the day of inclusion, during an appointment for a TEP exam | |
Primary | CT scan with measurement | Visual assessment of the rectal capacity on a 3-point scale (0, 1, 2) and content characteristics (air, feces, air and feces). | Only at the day of inclusion, during an appointment for a TEP exam |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05060471 -
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
|
Phase 2 | |
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Completed |
NCT05518201 -
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
|
Phase 1 | |
Withdrawn |
NCT02857608 -
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
|
Phase 2 | |
Active, not recruiting |
NCT02546973 -
Quality of Life in Patients With Anal Cancer
|
||
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00550589 -
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
|
Phase 2 | |
Completed |
NCT00324415 -
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
|
Phase 2 | |
Terminated |
NCT00568425 -
QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
|
||
Terminated |
NCT00267787 -
Molecular Genetic and Pathological Studies of Anal Tumors
|
||
Completed |
NCT00066430 -
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
|
Phase 1 | |
Completed |
NCT04083053 -
High-Resolution Anoscopy Perceived Discomfort Study
|
N/A | |
Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
Recruiting |
NCT04857528 -
Detecting HPV DNA in Anal and Cervical Cancers
|
||
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01937780 -
Anal Cancer Radiotherapy Study
|
||
Completed |
NCT01651949 -
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
|
Phase 3 |